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Transfusion-dependent thalassaemia (TDT) requires red blood cell concen-
trates (RBCC) to prevent complications of anaemia, but carries risk of
infection. Pathogen reduction of RBCC offers potential to reduce infectious
risk. We evaluated the efficacy and safety of pathogen-reduced (PR) Amu-
staline-Glutathione (A-GSH) RBCC for TDT. Patients were randomized to
a blinded 2-period crossover treatment sequence for six transfusions over
8–10 months with Control and A-GSH-RBCC. The efficacy outcome uti-
lized non-inferiority analysis with 90% power to detect a 15% difference in
transfused haemoglobin (Hb), and the safety outcome was the incidence of
antibodies to A-GSH-PR-RBCC. By intent to treat (80 patients), 125  19
RBCC were transfused in each period. Storage durations of A-GSH and C-
RBCC were similar (89 days). Mean A-GSH-RBCC transfused Hb (g/kg/
day) was not inferior to Control (0113  004 vs. 0111  004,
P = 0373, paired t-test). The upper bound of the one-sided 95% confi-
dence interval for the treatment difference from the mixed effects model
was 0005 g/kg/day, within a non-inferiority margin of 0017 g/kg/day. A-
GSH-RBCC mean pre-transfusion Hb levels declined by 60 g/l. No anti-
bodies to A-GSH-RBCC were detected, and there were no differences in
adverse events. A-GSH-RBCCs offer potential to reduce infectious risk in
TDT with a tolerable safety profile.
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Transfusion-dependent thalassaemia (TDT) requires regular
transfusion to prevent complications of anaemia and exces-
sive erythroid expansion (Cappellini & Motta, 2017). How-
ever, utilization of red blood cell concentrates (RBCC) in
TDT must be managed to minimize transfusion iron (Fe)
burden within the limits of chelation therapy (Cazzola et al,
1997; Cohen et al, 2008; Porter & Garbowski, 2018). Trans-
fusion is associated with the risk of transfusion-transmitted
infection (TTI) due to undetected known pathogens (Can-
dotti et al, 2019), emerging pathogens (Stramer et al, 2013)
and unrecognized bacterial contamination (Damgaard et al,
2015). Despite improved donor testing, long-term transfu-
sion support has a substantial cumulative life-time residual
risk of TTI (Kleinman & Stassinopoulos, 2015) and splenec-
tomized TDT patients, in particular, may have increased TTI
morbidity (Teawtrakul et al, 2015). Pathogen reduction of
RBCC offers potential to reduce the risk of TTI.
Nucleic acid targeted pathogen reduction of RBCC using
amustaline-glutathione (A-GSH) to inactivate viruses,
bacteria, protozoa and leucocytes has been evaluated in
healthy subjects demonstrating post-transfusion RBC recov-
ery and life-span suitable for transfusion, and for support of
acute anaemia during cardiovascular surgery (Cancelas et al,
2017; Brixner et al, 2018). A prior study with the original
pathogen-reduced (PR)-RBCC process in TDT patients was
halted due to the unexpected finding of antibodies to treated
RBCC without evidence of clinical haemolysis (Benjamin
et al, 2005; North et al, 2007; Geisen et al, 2018). A modified
process was developed to reduce the risk of A-GSH RBCC
immune responses. The present Phase 3 clinical trial was
designed to evaluate the efficacy and safety for TDT using A-
GSH RBCC (Test) prepared with this modified process. The
study utilized repeated transfusion exposure to compare hae-
moglobin (Hb) use of A-GSH and conventional RBCC (Con-
trol), and to assess the incidence of antibodies to A-GSH
RBCC within the range of RBC alloimmune responses (4–
20%) reported for patients with congenital anaemia disorders
(Chou et al, 2013).
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The study (EUDRA: number 2012-002920-33) was conducted
at 3 clinical centres in 2 countries (Italy and Turkey) with good
clinical practice compliance in conformity with the Interna-
tional Conference on Harmonization (ISO 14155:2011) and
the Helsinki Declaration. The research protocol was approved
by the respective institutional human research review boards at
each clinical site. All participants gave informed consent. A
Data and Safety Monitoring Board provided oversight and the
following prospectively defined stopping rules: if 3 subjects
developed antibody with defined specificity to A-GSH RBCC,
enrolment would be halted until the antibody haemolytic
potential was defined, but subjects on study were continued as
long as crossmatch-compatible RBCC were available. The
study would be stopped if 2 subjects experienced a haemolytic
transfusion reaction with accelerated RBC clearance and
defined specificity to A-GSH RBCC.
Randomization and masking
Randomization to study treatment sequence was conducted
by clinical site personnel using the electronic data capture
system. Test and Control RBCC were prepared in identical
containers. All clinical trial personnel were blinded to the
randomized treatment sequence. Only the blood centre per-
sonnel that prepared the RBCC were not blinded: they did
not have access to clinical trial data.
The trial utilized a randomized, double-blind, active-con-
trolled 2-treatment period cross-over design to evaluate A-
GSH RBCC (Test) in comparison to conventional (Control)
RBCC (Fig 1). TDT patients receiving chronic transfusion
support without confounding clinical issues were offered
enrolment. Inclusion criteria were: diagnosis of TDT in a
chronic transfusion programme for at least 1 year, age
≥11 years, non-child bearing female or non-pregnant female
with childbearing potential using birth control, 1-year history
of stable RBCC transfusion support, history of at least 14-
day intervals between RBCC transfusions, RBCC transfusion
administered on a single day for each episode, and signed
informed consent or paediatric assent as required. Use of
stable Fe chelation therapy was allowable. Exclusion criteria
were: baseline antibody reactivity specific to A-GSH RBCC,
splenic hyper-function defined by transfusion requirement
>180 ml RBCC/kg/year, palpable spleen >4 cm below costal
margin or ≥18 cm longitudinal dimension by ultrasound,
anticipated change in RBCC transfusion requirements or
anticipated splenectomy in the next 12 months, risk of car-
diac decompensation with ejection fraction <56% or multi-
slice T2* < 10 ms, allo-immunization to RBC antigens limit-
ing provision of compatible RBCC, requirement for frozen
or washed RBCC, requirement for gamma-irradiated RBCC,
history of glucose-6-phosphate dehydrogenase deficiency,
positive direct anti-globulin test (DAT) > 2+ with poly-
specificity or indirect anti-globulin test (IAT) with pan-reac-
tivity precluding definition of allogenic or auto antibody
specificity, documented human immunodeficiency virus or
hepatitis C virus infection, breast feeding, current cancer
chemotherapy, other chronic medical disorder precluding
study participation to completion, history of poor study
compliance and participation in another study concurrently
or in the preceding 28 days. Study withdrawal and stopping
rules were pre-specified.
Study treatments: preparation of RBCC
Blood centre personnel, blinded to clinical data, prepared all
components. Both A-GSH RBCC (Test) and Control RBCC
were prepared from CPD whole blood with leucocyte reduc-
tion and suspension in Saline-Adenine-Glucose-Mannitol
(SAG-M) solution. The total haemoglobin Hb content (g)
and volume (ml) were measured for each Test and Control
RBCC prior to storage at 4–6°C for up to 35 days after col-
lection. Pathogen reduction was performed in a functionally
closed system of plastic containers within 24 h of collection
using final concentrations of Amustaline (02 mmol/L) and
Glutathione (20 mmol/L) as described. (Cancelas et al, 2017;
Brixner et al, 2018) Process validation studies of Test RBCC
at each production site were conducted prior to initiating
clinical transfusions. Post-production and quality control
studies were performed on a subset of Test RBCC on day 35
of storage (Erickson et al, 2018). Control RBCCs were pro-
cessed in compliance with each centre’s standard operating
procedures and respective national regulations.
Clinical study procedures
Patients were screened up to 30 days prior to randomization,
stratified by country, and randomized to a transfusion
sequence of Test-Control (T-C) or Control-Test (C-T) for
six transfusion episodes in each treatment period over
approximately 8–10 months with follow-up for 45 days after
the last transfusion of the second period. Baseline clinical
data included subject medical history, pre-transfusion hae-
moglobin (Hb) levels and target Hb threshold for the
6 months prior to enrolment, concomitant medications,
pregnancy test for females, ABO and Rh, a blood sample
reserved for RBC antigen genotype, and gel-card antibody
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Fig 1. Study design. The study design for 2 wash-in transfusions
(TXNS) followed by 4 efficacy evaluation transfusions (TXNS) is
indicated.
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screen to A-GSH treated and untreated RBC panel antigens
to detect pre-existing native antibodies to A-GSH red cells
(Data S1). Withdrawal was permitted for: patient request,
pregnancy, medication associated with haemolysis, antibody
to A-GSH RBCC preventing transfusion, antibody to A-GSH
RBCC with haemolysis, antibody to RBC antigens limiting
available phenotype matched RBC and grade ≥3 allergic
transfusion reactions. Randomized subjects who withdrew
from the study before receiving any study RBC transfusions
for the first efficacy evaluation period were replaced; and
subjects withdrawn in the first treatment period could be
replaced.
Patients were managed with compatible RBCC with a tar-
get pre-transfusion Hb threshold of approximately 90–100 g/l,
or as designated by treating physicians blinded to treatment
and Hb content of RBCC. Each treatment period commenced
with 2 wash-in transfusion episodes followed by 4 efficacy
evaluation transfusion episodes (Fig 1). Within 72 h prior to
each transfusion episode, subjects were evaluated for: serologi-
cal crossmatch to the assigned RBCC, antibodies to A-GSH
RBC, haematology full blood count panel, clinical chemistry
panel. Direct anti-globulin tests (DAT) and indirect anti-
globulin tests (IAT) were performed within 3–7 days before
scheduled transfusion. Treating physicians, blinded to treat-
ment assignment and Hb content of Test and Control
RBCC, prescribed the number of RBCC required at each
episode, and regulated the RBCC dose and interval between
transfusion episodes to achieve physician-defined Hb levels.
The transfused volume of RBCC was recorded for each
transfusion episode. Patients were contacted 14  2 days
after each transfusion to assess adverse events (AE), serious
AE (SAE) and delayed haemolytic transfusion reactions
(DHTR). After completion of the last transfusion episode of
the second treatment period, patients reverted to non-study
conventional RBCC and were followed for two additional
transfusions or at least 45 days for AE and SAE, antibodies
to A-GSH and untreated RBCC, and evidence of haemolysis
(haematology and chemistry panels). Fe chelation therapy
was maintained as prior to study entry, and could be
adjusted per standard of care.
Outcome measures
The primary efficacy outcome was average Hb use expressed
as Hb mass (g) transfused per kg body weight per day in
transfusion episodes 3–6 after 2 wash-in transfusions for each
treatment period. Average Hb use over all 6 transfusion epi-
sodes in each treatment period also was summarized. The
primary safety outcome was the incidence of treatment-emer-
gent antibodies to A-GSH RBCC during all transfusion epi-
sodes in each period and through the 45 day post-study
surveillance. Secondary safety outcomes included the inci-
dence of AE, SAE, antibodies to RBC alloantigens and acute
transfusion reactions.
Statistical analyses
The primary efficacy analysis was conducted on the intent-to-
treat (ITT) patients using a non-inferiority test with a pre-de-
termined non-inferiority margin ≤15% of the Control mean
value for average Hb transfused. Non-inferiority was assessed
by comparing the upper bound of a one-sided 95% confidence
interval (CI) for the treatment difference (Test-Control) of
average Hb use of the observed Control mean. The study was
designed with 90% power with 70 patients completing both
treatment periods. For the primary efficacy analysis, the least
squares (LS) means treatment difference (Test-Control) and a
one sided 95% CI were estimated using a mixed effects model,
where treatment, period, and treatment sequence were fitted as
fixed effects, and patient as a random effect. A sensitivity anal-
ysis was conducted using a similar mixed effects model as spec-
ified for the primary efficacy analysis, with patient pre-
transfusion Hb level included as an additional fixed effect.
Continuous variables were summarized descriptively by mean,
median and treatment difference (Test-Control), and com-
pared by paired t test. For the primary safety endpoint, the
95% Clopper-Pearson CI was computed for the incidence of
treatment-emergent antibodies. Proportions of patients with
treatment-emergent AEs were compared between treatment
periods using the Fisher’s exact test.
Results
Patient demographics
Eighty-six patients were randomized (45 to Test-Control and
41 to Control-Test, Fig 2). No screened patients were excluded
due to pre-existing antibodies to A-GSH red cells. Eighty-one
patients received at least one study RBCC (safety population).
Eighty patients received RBCC evaluable for efficacy (transfu-
sion episodes 3–6), and constituted the ITT population. Nine
patients either: withdrew voluntarily (n = 1), received off-pro-
tocol RBCC (n = 6) or incorrectly assigned RBCC (n = 2).
Thus, 71 patients received all RBCC per randomization assign-
ment, and were summarized as per-protocol only (PPO). Base-
line demographics demonstrated differences between countries
in the proportional distribution of ABO groups, splenectomy
status (Italy 1 of 13; Turkey 39 of 67), and prior transfusion
management with phenotype matched RBCC (Table I). Hae-
moglobin mutations and clinical phenotypes were consistent
with TDT (Table SI). Among the total ITT population, 111%
of patients had a history of alloantibodies to red cell antigens at
entry to the study, and no patients were withdrawn due to
unavailability of compatible RBCC. All patients were main-
tained on iron chelation therapy.
Baseline clinical characteristics
For the total ITT population, baseline clinical laboratory
characteristics at entry to the first treatment period were not
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different between randomization sequences (Table II). ITT
patient baseline haemoglobin levels were lower in Turkey
than in Italy; and lower for splenectomized patients, who
were primarily enrolled in Turkey. In both countries, baseline
mean corpuscular haemoglobin (MCH) values were within
the normal range (27–31 pg), consistent with predominantly
circulating donor RBC indicative of effective erythropoiesis
suppression. Mean baseline platelet and leucocyte counts
were higher in Turkey due to the inclusion of more splenec-
tomized patients. Mean baseline LDH and total bilirubin
levels were similar between regions, and between splenec-
tomized and non-splenectomized patients (Table II).
RBCC haemoglobin content and transfusion exposure
During the study, 1024 Test and 1008 Control RBCC units
were transfused. Post-production Test and Control RBCC
demonstrated small differences in volume and mean Hb con-
tent due to expected average PR processing Hb losses of ~1 g
(Table III). Total Hb content (g) of Test RBCC ranged from
39 to 73 g; and for Control RBCC from 35 to 74 g (Fig 3).
For the ITT population for all transfusion episodes, a
mean of 125  19 Test and Control RBCC were transfused
per patient; however, the total Hb mass (g) of Test RBCC
(683  98) transfused was slightly less than Control RBCC
(697  109), but not statistically different (Table IV). The
mean volume of Test RBCC transfused was statistically lower
(P = 0021). The mean storage age of RBCC was slightly
shorter in Italy than Turkey, but overall similar for Test and
Control RBCC (Table IV). The mean total Hb mass trans-
fused per patient over all transfusion episodes was larger in
Italy than Turkey. However, patient exposures to Test and
Control RBCC components were similar within the non-
splenectomized and splenectomized patient sub-groups;
although splenectomized patients received less total Test Hb
than non-splenectomized patients (Table IV). Only 11
(05%) of 2043 RBCC units transfused were off-protocol,
primarily due to unavailable study RBCC (Table SII).
Efficacy outcome
By ITT, efficacy evaluable transfusion episodes (n = 3–6)
demonstrated a mean treatment difference (Test-Control) in
Hb use of 0002 g/kg/day (18% of Control mean), which
was not significantly different (95% CI = 0002 to 0005,
P = 0373, paired t test) (Table V). Non-inferiority was
observed with an upper bound of the 1-sided 95% CI of
0005 g/kg/day (45% of Control) below the 15% inferiority
margin (0017 g/kg/day) based on the Control mean
(0111 g/kg/day). Additionally, the 2-sided 95% CI for the
LS-mean treatment difference was 0002 to 0005 g/kg/day,
within the pre-defined inferiority margin. Consistent results
were observed with sensitivity analyses utilizing a paired t-
test (2-sided 95% CI for the mean treatment differ-
ence = 0002 to 0005 g/kg/day), and a mixed effects model
similar to the primary efficacy analysis with the addition of
pre-transfusion Hb level included in the model (2-sided 95% CI
for the mean treatment difference = 0003 to 0006 g/kg/day)
confirming non-inferiority. From the primary mixed effects
model, a significant period effect was observed (P = 0007)
where the LS mean of Hb use in Period 2 was 0005 g/kg/
day higher than Period 1, probably due to the increased Hb
dose observed with the sequence of Period 1 Test to Period 2
Control RBCC (Fig 4D). When only Period 1 data were
summarized, mean Hb use values were 0115 and
0104 g/kg/day for Test and Control RBCC, respectively,
and a wider CI for the treatment difference (2-sided 95%
CI = 0004 to 0026 g/kg/day, P = 0155 by 2-sample
t-test) was observed due to reduced statistical power. Analy-
ses for the PPO population demonstrated a mean treatment
difference (T-C = 0003 g/kg/day, 95% CI = 0001 to
0006, P = 0162 by paired t-test (Table SIII). Additional
analyses by ITT and PPO for all transfusion episodes indi-
cated no difference in Hb use between Test and Control
RBCC (Table VI and SIV).
Half of the patient population was splenectomized prior
to study entry; these patients received significantly less
(P = 0019) Test RBCC Hb (673  24 g) than Control
RBCC (696  85 g) (Table IV). Splenectomized patients
were older, had higher body weight (Table I) and longer
transfusion intervals, and used approximately 30% less Hb
with both Test and Control RBCC (Tables V and VI). How-
ever, within the respective sub-groups of splenectomized and
non-splenectomized patients, Hb use of Test RBCC and
Control RBCC was not markedly different (Tables V, VI,
SIV, SV).
The mean Hb dose was similar for ITT and PPO
patients during Test and Control efficacy episodes 3–6
(Table V). However, during wash-in transfusions 1 and 2
(Fig 4A), the Hb dose was significantly less for Test RBCC
(222  37 g vs. Control 236  38 g, P < 0001). Mean pre-
transfusion Hb levels with A-GSH RBCC declined over 6
transfusion episodes during Test periods by 60 g/l Fig 4B),
although average mean pre-transfusion Hb levels (g/l) for
Test (92  70) and Control (94  70) remained within
the targeted range (90–100 g/l), but were statistically differ-
ent (P = 0002, paired t-test). Despite changes in pre-trans-
fusion Hb levels, patient average MCH values (Fig 4C)
remained within the normal range (27–31 pg). The impact
of transfusion sequence on pre-transfusion Hb levels was
evaluated (Fig 4D, E). Mean Hb doses in Period 2 Control
increased following Period 1 Test in response to consistently
lower Test RBCC Hb doses and declining pre-transfusion
Hb levels in Period 1 Test (Fig 4D, E). With larger Control
Hb doses in Period 1 followed by adequate Test RBCC Hb
doses in Period 2 (Fig 4D), pre-transfusion Hb levels in
Period 2 with Test RBCC declined less (Fig 4E). Across
both periods with Test and Control RBCC, regardless of
treatment sequence, patient MCH remained consistently
>27 pg (Fig 4F).
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Assessed for Eligibility (n = 86)
Randomized (n = 86)
45 Test to control
41 Control to test
Excluded (n = 5)
• Failed inclusion/exclusion criteria
Received Intervention (n = 42) Received Intervention (n = 39)
Discontinued Intervention (n = 2)
• Withdrew (patient decision) after 1 Test 
transfusion episode, no efficacy data
• Withdrew (patient decision) after 6 Test 
and 3 Control transfusion episodes, 
efficacy data included in ITT Population
Analysed (n = 42)
Safety Population = 42
Intent to Treat  Efficacy Population = 41
Per Protocol Efficacy Population = 36
Analysed (n = 39)
Safety Population = 39
Intent to Treat  Efficacy Population = 39
Per Protocol Efficacy Population = 35
Control - TestTest - Control
Fig 2. Disposition of patients. The disposition of patients from eligibility screening (n = 86), to randomization (n = 86) and exclusion (n = 5) is
indicated. The randomization sequence assigned (Test to Control or Control to Test) is indicated with the first period assigned. The safety popu-
lation (n = 81), the intent to treat (ITT) population (n = 80), and the per-protocol only (PPO) population (n = 71) are shown. One patient
withdrew after a single study transfusion and was only assessed for safety. In the ITT population, 6 patients received off-protocol red blood cell
concentrates (RBCC), 2 patients received incorrectly assigned study RBCC for a single transfusion episode, and 1 patient received all of the
assigned transfusions in the Control period and only 3 of 6 transfusions in the Test period, thus was included in the ITT analysis but not the
PPO analysis.
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Safety outcomes
No patients developed antibodies specific to A-GSH RBCC.
No patients developed emergent antibodies against RBC
antigens during either the treatment period or post-transfu-
sion surveillance, and no patients had clinical or laboratory
evidence of immune haemolysis. Total bilirubin values were
slightly elevated above the reference range at all times, but
not different between Test and Control; and serum LDH
levels remained within normal reference ranges. The inci-
dence of all grades of treatment-emergent AE was compara-
ble between treatment periods (Table SV). The majority of
AE were of Grade 1 and 2 severity, and there was no dif-
ference in the distribution of clinical severity between Test
and Control RBCC (P = 0857). Within the System Organ
Class of Metabolism Disorders there was an increase in the
AE of Diabetes Mellitus attributable to an increased inci-
dence of higher fasting blood glucose levels during Control
periods.
The AE of “symptomatic anaemia”, defined by a pre-
transfusion Hb level substantially below 90–100 g/l requiring
an unscheduled transfusion, was reported for 6 Test period
and 3 Control period patients, and one patient had “symp-
tomatic anaemia” reported in both the Test and Control
periods. The pre-transfusion Hb levels for these patients ran-
ged from 60 to 78 g/l (Table SVI; Figure S1). Each of these
patients had received RBCC doses below the study average
Hb dose for Test and Control RBCC over successive transfu-
sion episodes; and 2 patients had concurrent inflammatory
AEs.
Table I. Baseline demographic characteristics for the ITT population







Age (years) 285 (92) 256 (79) 222 (85) 300(54) 261 (81)
Patients aged ≤18 years (%) 231 179 375 0 188
Male gender (%) 385 463 325 575 450
Body weight (kg) 567 (151) 593 (132) 525 (124) 653 (115) 589 (135)
A/B/AB/O blood group (%) 231/154/0/615 388/269/75/269 350/275/25/350 375/225/100/300 363/250/63/325
Rh+ (%) 100 955 975 950 963
RBC alloantibodies (%)† 71 119 50 175 111
Phenotype matched (%)‡ 100 179 400 250 321
Mean (standard deviation) are presented for continuous variables, and proportions (%) are presented for categorical variables. ITT, intent to
treat; RBC, red blood cells; RBCC, red blood cell concentrate.
*Baseline characteristics of the study population prior to the first study transfusion.
†Proportion of patients with a documented history of alloantibodies to RBC prior to study enrollment.
‡Proportion of patients managed with phenotype matched RBCC. All patients were matched for A, B, O and Rh D. For patients requiring pheno-
type-matched blood in Italy and Turkey, antibodies to the following Rh antigens were routinely included: C, c, E, e, K. Antibodies to specific
antigens were evaluated for selected patients including: Fya, Fyb, M, N, S, s, Lea, Leb, Lu(a), Lu(b), Kp(a), Kp(b), and C(w).
Table II. Baseline clinical laboratory characteristics of the ITT population at entry to first assigned treatment sequence.*
Italy Turkey Non-splenectomized Splenectomized ITT Population‡
P‡Sequence T to C C to T T to C C to T T to C C to T T to C C to T T to C C to T
Patients (n) 7 6 34 33 21 19 20 20 41 39
Hb (g/l)† 100 (60) 104 (80) 93 (90) 92 (80) 97 (90) 96 (10) 92 (80) 92 (80) 94 (90) 94 (10) 0787
RBC (1012/l)† 36 (02) 37 (02) 33 (04) 32 (04) 35 (04) 34 (04) 32 (03) 32 (03) 33 (04) 33 (04) 0593
MCH (pg)† 276 (10) 279 (12) 286 (15) 289 (20) 281 (16) 281 (22) 289 (13) 293 (15) 285 (15) 287 (20) 0466
WBC (109/l)† 81 (21) 76 (19) 129 (61) 123 (62) 72 (18) 72 (21) 172 (39) 154 (56) 121 (59) 115 (60) 0684
PLT (109/l)† 247 (71) 311 (221) 521 (213) 530 (234) 306 (99) 326 (141) 651 (169) 647 (214) 474 (221) 495 (43) 0690
LDH (u/l)† 249 (118) 237 (85) 179 (80) 178 (110) 208 (97) 188 (116) 174 (81) 188 (102) 192 (90) 188 (107) 0683
Bilirubin
(lmol/l)†
46 (29) 43 (29) 38 (19) 43 (29) 46 (22) 38 (26) 33 (15) 50 (31) 39 (30) 43 (27) 0478
Data by country and spleen status are presented for informational purposes.
*Data are presented for the ITT population by randomization sequence (T-C and C-T), study site and by spleen status.
†Mean (standard deviation) are presented for pre-transfusion haemoglobin (Hb), red blood cell count (RBC), mean corpuscular haemoglobin
(MCH), white blood cell (WBC) count, platelet (PLT) count, lactate dehydrogenase (LDH), and total bilirubin at study entry prior to first trans-
fusion in either the Test (T) or Control (C) treatment periods.
‡The P-value is based on the ITT population for mean treatment differences of the first treatment period (T-C) using a two-sample t-test.
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Discussion
Pathogen reduction of platelet and plasma components has
been introduced into routine practice in a number of coun-
tries as a prospective measure to reduce the risk of TTI.
(U.S. Department of Health and Human Services Food and
Drug Administration 2017) The current study is part of the
clinical development programme for PR A-GSH RBCC to
complete licensure of pathogen reduction for all blood
components. This study was designed to assess the impact of
A-GSH RBCC on Hb utilization, a direct measure of efficacy
in TDT which requires long-term RBC support. By ITT and
PPO analyses, haemoglobin use of A-GSH RBCC was not
inferior to conventional RBCC. The calculated daily transfu-
sion Fe burden associated with Test RBCC for all patients
was 038 mg/kg/day, in agreement with the range of 033–
043 mg/kg/day reported for conventional RBCC and, as pre-
viously described, we confirmed a lower transfusion Fe
Table III. Post-production characteristics of clinical inventory test and control RBCC.*
Parameter Test (n = 1024) Control (n = 1008) Difference (CI)† P‡
RBCC volume (ml) 2714 (190) 2789 (222) 75 (93, 57) <0001
RBCC Hct (%) 605 (24) 590 (28) 15 (17, 17) <0001
RBCC Hb content (g) 546 (59) 556 (59) 10 (15, 05) <0001
Hb, haemoglobin; Hct, haematocrit.
*The mean (standard deviation) for the characteristics of Test (T) and Control (C) red blood cell concentrate (RBCC) transfused.
†The mean treatment differences (T-C) and the two-sided 95% confidence interval (CI) for the observed treatment differences.
‡P values based on ANOVA controlling for treatment and site.
Fig 3. Haemoglobin content of test and control RBCC. The proportional (%) distributions of total haemoglobin (Hb) content (g) for 1024 Test
(dots) and 1008 Control (diagonal) red blood cell concentrates (RBCC) are shown.
Table IV. ITT population exposure to test and control RBCC by country and spleen status (transfusion episodes 1–12)
Italy Turkey Non-splenectomized Splenectomized Total
PTest Control Test Control Test Control Test Control Test Control
Patients* 13 13 67 67 40 40 40 40 80 80
RBCC† 144 (30) 139 (38) 121 (08) 123 (11) 128 (20) 127 (23) 122 (10) 124 (13) 125 (19) 125 (19) 0804
RBCC age‡ 63 (22) 57 (19) 94 (15) 94 (15) 85 (22) 83 (22) 94 (17) 93 (18) 89 (20) 88 (21) 0573
Volume§ 383 (08) 389 (10) 331 (03) 342 (03) 345 (05) 353 (06) 330 (03) 346 (04) 339 (04) 350 (05) 0021
Total Hb¶ 765 (200) 743 (230) 667 (51) 688 (65) 693 (119) 697 (131) 673 (72) 696 (85) 683 (98) 697 (109) 0117
Mean (SD) are presented and P-values for the treatment difference are derived from paired t-test. Hb, haemoglobin; ITT, intent to treat; RBCC,
red blood cell concentrate; SD, standard deviation.
*Number of patients transfused in the ITT population.
†Average (SD) number of RBCC transfused in Test and Control treatment periods.
‡Average (SD) days of storage of RBCC prior to transfusion in Test and Control treatment periods.
§Average (SD) RBCC volume (l) transfused in Test and Control treatment periods.
¶Average (SD) total Hb transfused (g) in Test and Control treatment periods.
PR A-GSH RBCC for Transfusion-Dependent Thalassaemia
ª 2019 The Authors. British Journal of Haematology published by British Society for Haematology
and John Wiley & Sons Ltd 7
burden in splenectomized (031 mg/kg/day) compared to
non-splenectomized patients (045 mg/kg/day) (Cohen et al,
2008; Porter & Garbowski, 2018). No patients had immune
responses specific to PR RBCC or alloantibodies to RBC
antigens despite limited RBC phenotype matching in a
majority of patients. There were no substantial differences in
the safety profiles between Test and Control RBCC.
The distribution of Hb content for Test and Control
RBCC was broad. We believe this was due to variable donor
Hb levels and blood collection volumes. On average, A-GSH
RBCC contained 1 g less of total Hb, and this resulted in a
lower mean Hb dose during the Test treatment period, but
did not generally result in adjustments to transfusion RBCC
dosing or transfusion intervals. In routine practice, the Hb
content of RBCC is not measured; and RBCC are ordered
without knowledge of Hb content of each RBCC. In our
study, exacerbation of anaemia in 10% of patients correlated
with repeated lower Hb doses in randomly selected RBCC.
This study was conducted under routine practice condi-
tions in Italy and Turkey with differences in targeted pre-
transfusion Hb thresholds (100 vs. 90 g/l, respectively. The
majority of splenectomized patients were enrolled in Turkey.
The clinical centres in both countries used accepted target
pre-transfusion Hb levels (Cappellini & Motta, 2017). Inclu-
sion of splenectomized and non-splenectomized patients con-
firmed that splenectomized patients have lower overall Hb
requirements, but Hb use was similar for Test and Control
RBCC (Cazzola et al, 1997; Cohen et al, 2008). Although we
observed a trend of decreasing pre-transfusion Hb levels with
Test RBCC, average pre-transfusion Hb levels remained
within targeted ranges. The decline in pre-transfusion Hb
may indicate decreased viability of A-GSH RBCC. To explore
the hypothesis if reduced RBC viability impacted patient Hb
levels, we examined the effects of treatment sequence and Hb
doses during the wash-in transfusions (Fig 4A, D). This anal-
ysis suggested that reduced Hb doses during the wash-in
phase exerted an effect on subsequent pre-transfusion Hb
levels. Over all 6 transfusion episodes of Test RBCC the
decrease in pre-transfusion Hb levels appeared less than
would be expected if the viability of Test RBCC had been
substantially reduced. Management of transfusion doses with
knowledge of Hb content may facilitate management of
patient Hb levels, transfused Fe, level of erythropoiesis sup-
pression, and tissue Fe burden (Porter & Garbowski, 2018).
A potential limitation of this study was the duration of
transfusion support. The duration of the treatment periods
was selected to provide a feasible time to characterize Hb use
within the crossover design which was used to minimize
inter-patient variability. Although a period effect was
detected, it was small, and appeared largely attributable to
the increased Hb dose in the treatment sequence of Period 1
Test RBCC to Period 2 Control RBCC in response to mod-
estly decreasing pre-transfusion Hb levels with Period 1 Test,
due to lower Hb doses with wash-in RBCC. Despite these
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effect of A-GSH PR on Test RBC viability may not be
excluded definitively. The duration of transfusion support
may have impacted our ability to detect immune responses
to A-GSH RBCC. Multiple studies have indicated that the
number of RBCC transfused is an important determinant
of alloimmunization; and that splenectomized patients have
an increased rate of alloimmunization (Thompson et al,
2011; Vichinsky et al, 2014; Franchini et al, 2019). Al-
Riyami et al (2018) estimated that the rate of
alloimmunization per 100 units transfused was 056. Thus,
within the limited duration of our study, we may have
expected to observe approximately 5 new alloantibodies
and, despite the inclusion of a substantial number of higher
risk splenectomized patients and a transfusion policy of
ABO-D matched RBCC in a majority of patients, no treat-
ment emergent alloantibodies were observed. Studies of
longer duration with A-GSH RBCC will be required to con-
firm our observations.
Fig 4. Transfused haemoglobin dose, pre-transfusion haemoglobin and patient mean corpuscular haemoglobin. (A–C) Test and Control Transfu-
sion Episodes by Type of RBCC. (A) Mean haemoglobin (Hb) dose (g) transfused per episode; (B) Mean pre-transfusion patient Hb (g/l) per epi-
sode; (C) Pre-transfusion patient mean corpuscular haemoglobin (MCH, pg) are indicated for all Test (▲) and Control ( ) red blood cell
concentrate (RBCC) transfusion episodes. (D–F) Test and Control Transfusion Episodes by Sequence and Type of RBCC: For 41 patients, Test
were transfused in Period 1 (▲) for episodes 1–6 followed by Control RBCC in Period 2 ( ) for episodes 7–12. For 39 patients, Control RBCC
( ) were transfused in Period 1 for episodes 1–6 followed by Test RBCC ( ) in Period 2 for episodes 7–12. (D) Mean Hb dose (g) transfused
per episode; (E) Mean pre-transfusion patient Hb (g/l) per episode; (F) Pre-transfusion patient MCH (pg) are indicated for Test and Control
RBCC by randomized treatment sequence for all transfusion episodes.
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Within the scope of this study, the experience with A-
GSH RBCC may be generalizable to other types of chronic
anaemia to reduce TTI risk without impacting Hb use and
Fe transfusion burden, but further studies are required to
support this opinion. This study showed that there is large
variability (35–75 g) in the Hb content of donor RBCC. This
is likely to impact both Fe loading rates and secondary Fe
distribution (Porter & Garbowski, 2018). Active management
of Hb dose over extended periods of transfusion support
should be carefully evaluated further in routine use to deter-
mine if selection of RBCC with knowledge of Hb content
can result in more consistent pre-transfusion Hb levels and
further reduce transfusion Fe burden. In conclusion, this
study showed that A-GSH pathogen reduction of RBCC did
not significantly increase RBCC utilization in TDT patients,
and appeared to be well-tolerated and logistically feasible for
chronic transfusion therapy within each country’s economic
resources.
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